High sustained virologic response on AbbVie's Viekirax + Exviera in interim study

11 September 2015

Interim results from an interim study of AbbVie’s (NYSE: ABBV) Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir) showed a 98% sustained virologic response at 12 weeks post-treatment in chronic hepatitis C patients.

The primary endpoint of the AMBER study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment after being given the combination with or without ribavirin. This study of Polish patients who reached post-treatment at week 12 showed a 98% sustained virologic response.

Safety analysis of the interim study showed that of the 186 patients enrolled showed that adverse events were mostly mild, most commonly fatigue, nausea and headache. Serious adverse events occurred in 4% of the participants, and included hepatic decompensation, anemia and kidney insufficiency hepatotoxicity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK